• Publications
  • Influence
Establishment and characterization of first trimester human trophoblast cells with extended lifespan.
TLDR
Apart from their ability to sustain prolonged growth in culture, the transfected HTR-8/SVneo cells share a number of phenotypic properties with the parental trophoblast cells, which may prove to be an important tool for the study of placental function and/or tumor progression. Expand
Angiogenesis as a therapeutic target
TLDR
Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first. Expand
The anti-angiogenic basis of metronomic chemotherapy
TLDR
Gaining better insight into the mechanisms of these effects could lessen or even eliminate the empiricism used to determine the optimal dose and schedule for metronomic chemotherapy regimens. Expand
Clinical translation of angiogenesis inhibitors
TLDR
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply, and clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. Expand
Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease overall survival in mice receiving short-term therapy in variousExpand
The multifaceted circulating endothelial cell in cancer: towards marker and target identification
TLDR
Evidence is emerging that CEC kinetics and viability might correlate with clinical outcomes in cancer patients who undergo anti-angiogenic treatment, and this could help to determine the optimal biological dose of anti-Angiogenic drugs, which are being used with increasing frequency in medical oncology. Expand
Tumor angiogenesis: past, present and the near future.
TLDR
The 1990s have witnessed a striking change in both attitude and interest in tumor angiogenesis and anti-angiogenic drug development, to the point where a remarkably diverse group of over 24 such drugs is currently undergoing evaluation in phase I, II or III clinical trials. Expand
Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR
TLDR
It is proposed that oncogene-containing tumor cell-derived MVs could act as a unique form of angiogenesis-modulating stimuli and are capable of switching endothelial cells to act in an autocrine mode. Expand
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
TLDR
It is shown that treatment of tumor-bearing mice with vascular disrupting agents leads to an acute mobilization of CEPs, which home to the viable tumor rim that characteristically remains after such therapy, and this provides a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs. Expand
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo:
TLDR
Therapeutic disruption of EGFR or ErbB2/neu protein function in vivo may result in partial suppression of angiogenesis, a feature that could enhance the therapeutic index of such agents in vivo and endow them with anti-tumor effects, the magnitude of which may be out of proportion with their observed cytostatic effects in monolayer tissue culture. Expand
...
1
2
3
4
5
...